ATE322493T1 - Cyclohexennukleinsäuren - Google Patents
CyclohexennukleinsäurenInfo
- Publication number
- ATE322493T1 ATE322493T1 AT00990110T AT00990110T ATE322493T1 AT E322493 T1 ATE322493 T1 AT E322493T1 AT 00990110 T AT00990110 T AT 00990110T AT 00990110 T AT00990110 T AT 00990110T AT E322493 T1 ATE322493 T1 AT E322493T1
- Authority
- AT
- Austria
- Prior art keywords
- dna
- cyclohexenyl
- cena
- nucleic acids
- cyclohexene
- Prior art date
Links
- -1 CYCLOHEXENE NUCLEIC ACIDS Chemical class 0.000 title abstract 5
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cis-cyclohexene Natural products C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 title abstract 3
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 239000002777 nucleoside Substances 0.000 abstract 3
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 241000588724 Escherichia coli Species 0.000 abstract 1
- SIIZPVYVXNXXQG-KGXOGWRBSA-N [(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-4-[[(3s,4r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-3-hydroxyoxolan-2-yl]methyl [(2r,4r,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(phosphonooxymethyl)oxolan-3-yl] hydrogen phosphate Polymers C1=NC2=C(N)N=CN=C2N1[C@@H]1O[C@H](COP(O)(=O)OC2[C@@H](O[C@H](COP(O)(O)=O)[C@H]2O)N2C3=NC=NC(N)=C3N=C2)[C@@H](O)[C@H]1OP(O)(=O)OCC([C@@H](O)[C@H]1O)OC1N1C(N=CN=C2N)=C2N=C1 SIIZPVYVXNXXQG-KGXOGWRBSA-N 0.000 abstract 1
- 230000006978 adaptation Effects 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 125000003843 furanosyl group Chemical group 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 150000008300 phosphoramidites Chemical class 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Fats And Perfumes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17372899P | 1999-12-30 | 1999-12-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE322493T1 true ATE322493T1 (de) | 2006-04-15 |
Family
ID=22633239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00990110T ATE322493T1 (de) | 1999-12-30 | 2000-12-27 | Cyclohexennukleinsäuren |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP1244667B1 (de) |
| JP (1) | JP2003519231A (de) |
| AT (1) | ATE322493T1 (de) |
| AU (1) | AU2698301A (de) |
| DE (1) | DE60027203T2 (de) |
| ES (1) | ES2261270T3 (de) |
| WO (1) | WO2001049687A2 (de) |
Families Citing this family (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| CA2463719A1 (en) | 2003-04-05 | 2004-10-05 | F. Hoffmann-La Roche Ag | Nucleotide analogs with six membered rings |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| WO2006047842A2 (en) * | 2004-11-08 | 2006-05-11 | K.U. Leuven Research And Development | Modified nucleosides for rna interference |
| WO2007073149A1 (en) * | 2005-12-22 | 2007-06-28 | Keygene N.V. | Alternative nucleotides for improved targeted nucleotide exchange |
| US8604192B2 (en) | 2008-09-24 | 2013-12-10 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acids analogs |
| CN103154014B (zh) | 2010-04-28 | 2015-03-25 | Isis制药公司 | 修饰核苷、其类似物以及由它们制备的寡聚化合物 |
| EP2595664B1 (de) | 2010-07-19 | 2018-10-17 | Ionis Pharmaceuticals, Inc. | Modulation einer kern-rna |
| WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
| AU2012267546B2 (en) | 2011-06-10 | 2015-12-24 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (KLKB1) expression |
| CA2840614A1 (en) | 2011-06-29 | 2013-01-03 | Isis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
| CA2848753C (en) | 2011-09-14 | 2022-07-26 | Rana Therapeutics, Inc. | Multimeric oligonucleotide compounds |
| DK2794880T3 (en) | 2011-12-22 | 2018-07-23 | Ionis Pharmaceuticals Inc | METHOD OF MODULATING METASTASE-ASSOCIATED-IN-LONG-ADENOCARCINOM TRANSCRIPT-1- (MALATE-1) EXPRESSION |
| EP3330278A1 (de) | 2012-02-08 | 2018-06-06 | Ionis Pharmaceuticals, Inc. | Modulation von rna durch wiederholtes targeting |
| US9340784B2 (en) | 2012-03-19 | 2016-05-17 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
| WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
| WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
| US9518261B2 (en) | 2012-05-22 | 2016-12-13 | Ionis Pharmaceuticals, Inc. | Modulation of enhancer RNA mediated gene expression |
| ES2809199T3 (es) | 2012-06-25 | 2021-03-03 | Ionis Pharmaceuticals Inc | Modulación de la expresión de UBE3A-ATS |
| US20150297629A1 (en) | 2012-07-27 | 2015-10-22 | Isis Pharmaceuticals, Inc. | Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen |
| KR102237882B1 (ko) | 2012-08-15 | 2021-04-07 | 아이오니스 파마수티컬즈, 인코포레이티드 | 변형된 캡핑 프로토콜을 이용하는 올리고머 화합물 제조 방법 |
| WO2014059364A1 (en) | 2012-10-11 | 2014-04-17 | Isis Pharmaceuticals, Inc. | Methods of treating kennedy's disease |
| US9175291B2 (en) | 2012-10-11 | 2015-11-03 | Isis Pharmaceuticals Inc. | Modulation of androgen receptor expression |
| US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
| EP2951191B1 (de) | 2013-01-31 | 2018-10-17 | Ionis Pharmaceuticals, Inc. | Verfahren zur herstellung oligomerer verbindungen unter verwendung von modifizierten kopplungsprotokollen |
| EP3400947B1 (de) | 2013-02-14 | 2023-08-23 | Ionis Pharmaceuticals, Inc. | Modulation der apolipoprotein-c-iii (aopciii)-expression in lipoproteinlipasedefizienten (lpld) populationen |
| DK2991656T3 (da) | 2013-05-01 | 2020-03-23 | Ionis Pharmaceuticals Inc | Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression |
| EP3656386A1 (de) | 2013-06-21 | 2020-05-27 | Ionis Pharmaceuticals, Inc. | Verbindungen und verfahren zur modulation der apolipoprotein-c-iii-expression zur verbesserung eines diabetischen profils |
| JP6487913B2 (ja) | 2013-07-02 | 2019-03-20 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 成長ホルモン受容体のモジュレータ |
| TW201536329A (zh) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | 用於調節失養性肌強直蛋白質激酶(dmpk)表現之化合物及方法 |
| EP3038627B1 (de) | 2013-08-28 | 2020-03-04 | Ionis Pharmaceuticals, Inc. | Modulation der prekallikrein (pkk)-expression |
| MX371518B (es) | 2013-09-13 | 2020-01-31 | Ionis Pharmaceuticals Inc | Moduladores del factor del complemento b. |
| KR102198082B1 (ko) | 2013-12-24 | 2021-01-05 | 아이오니스 파마수티컬즈, 인코포레이티드 | 안지오포이에틴-유사 3 발현의 조절 |
| US10036019B2 (en) | 2014-03-17 | 2018-07-31 | Ionis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
| EP3757214B1 (de) | 2014-04-01 | 2022-06-15 | Biogen MA Inc. | Zusammensetzungen zur modulierung der sod-1-expression |
| US10221416B2 (en) | 2014-04-24 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
| EP3137476B1 (de) | 2014-04-28 | 2019-10-09 | Ionis Pharmaceuticals, Inc. | Verbindungsmodifizierte oligomerverbindungen |
| EP3137091B1 (de) | 2014-05-01 | 2020-12-02 | Ionis Pharmaceuticals, Inc. | Konjugate von antisens-oligonukleotiden und deren verwendung zur modulation der pkk-expression |
| JP2017521045A (ja) | 2014-05-01 | 2017-08-03 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | アンジオポエチン様因子３発現を調節するための組成物及び方法 |
| KR102149571B1 (ko) | 2014-05-01 | 2020-08-31 | 아이오니스 파마수티컬즈, 인코포레이티드 | 성장 호르몬 수용체 발현을 조절하기 위한 조성물 및 방법 |
| CR20200228A (es) | 2014-05-01 | 2020-07-09 | Ionis Pharmaceuticals Inc | COMPOSICIONES Y MÈTODOS PARA MODULAR LA EXPRESIÒN DEL FACTOR B DEL COMPLEMENTO (Divisional 2016-0554) |
| WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
| EP3207138B1 (de) | 2014-10-17 | 2020-07-15 | Alnylam Pharmaceuticals, Inc. | Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon |
| EP3904519A1 (de) | 2014-10-30 | 2021-11-03 | Genzyme Corporation | Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon |
| WO2016086104A1 (en) | 2014-11-25 | 2016-06-02 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
| US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
| EP3262181B1 (de) | 2015-02-23 | 2024-04-10 | Ionis Pharmaceuticals, Inc. | Verfahren zur flüssigphasendetritylierung von oligomeren verbindungen |
| BR112017017178A2 (pt) | 2015-02-26 | 2018-04-03 | Ionis Pharmaceuticals Inc | moduladores específicos de alelo de rodopsina de p23h |
| MX2017012426A (es) | 2015-04-03 | 2018-01-26 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de tmprss6. |
| WO2016164746A1 (en) | 2015-04-08 | 2016-10-13 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
| MX366128B (es) | 2015-04-16 | 2019-06-28 | Ionis Pharmaceuticals Inc | Composiciones para modular la expresion de c90rf72. |
| WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
| HK1258275A1 (zh) | 2015-10-08 | 2019-11-08 | Ionis Pharmaceuticals, Inc. | 用於调节血管紧张素原表达的化合物和方法 |
| CN113952353A (zh) | 2015-11-06 | 2022-01-21 | Ionis制药公司 | 调节载脂蛋白(a)表达 |
| WO2020176771A1 (en) | 2019-02-27 | 2020-09-03 | Ionis Pharmaceuticals, Inc. | Modulators of malat1 expression |
| PL3947684T3 (pl) | 2019-03-29 | 2025-07-21 | Ionis Pharmaceuticals, Inc. | Związki i sposoby modulacji ube3a-ats |
| JP7667074B2 (ja) | 2019-03-29 | 2025-04-22 | 田辺三菱製薬株式会社 | Ｄｕｘ４の発現を調節するための化合物、方法及び医薬組成物 |
| EP4121534A1 (de) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Zusammensetzungen und verfahren zur behandlung von patienten mit einer heterozygoten alaninglyoxylat-aminotransferase-genvariante (agxt) |
| US20230227824A1 (en) | 2020-05-12 | 2023-07-20 | Mitsubishi Tanabe Pharma Corporation | Compound, method and pharmaceutical composition for regulating expression of ataxin 3 |
| KR20230108728A (ko) | 2020-11-18 | 2023-07-18 | 아이오니스 파마수티컬즈, 인코포레이티드 | 앤지오텐시노겐 발현을 조절하기 위한 화합물 및 방법 |
| WO2023003805A1 (en) | 2021-07-19 | 2023-01-26 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5034506A (en) * | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| DE19815901A1 (de) * | 1998-04-08 | 1999-10-14 | Aventis Res & Tech Gmbh & Co | Verfahren zur Herstellung von Pentopyranosyl-Nucleosiden |
-
2000
- 2000-12-27 EP EP00990110A patent/EP1244667B1/de not_active Expired - Lifetime
- 2000-12-27 AU AU26983/01A patent/AU2698301A/en not_active Abandoned
- 2000-12-27 AT AT00990110T patent/ATE322493T1/de not_active IP Right Cessation
- 2000-12-27 JP JP2001550227A patent/JP2003519231A/ja active Pending
- 2000-12-27 DE DE60027203T patent/DE60027203T2/de not_active Expired - Fee Related
- 2000-12-27 ES ES00990110T patent/ES2261270T3/es not_active Expired - Lifetime
- 2000-12-27 WO PCT/IB2000/002041 patent/WO2001049687A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001049687A2 (en) | 2001-07-12 |
| WO2001049687A3 (en) | 2002-03-28 |
| JP2003519231A (ja) | 2003-06-17 |
| ES2261270T3 (es) | 2006-11-16 |
| DE60027203T2 (de) | 2007-01-04 |
| EP1244667B1 (de) | 2006-04-05 |
| EP1244667A2 (de) | 2002-10-02 |
| WO2001049687A9 (en) | 2002-09-06 |
| AU2698301A (en) | 2001-07-16 |
| DE60027203D1 (de) | 2006-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE322493T1 (de) | Cyclohexennukleinsäuren | |
| US11634451B2 (en) | Method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides | |
| Yoo et al. | 2′‐O‐methyl‐modified phosphorothioate antisense oligonucleotides have reduced non‐specific effects in vitro | |
| CN109641026B (zh) | 用于检测靶rna的方法和组合物 | |
| Miller et al. | The nucleotide sequence of oocyte 5S DNA in Xenopus laevis. II. The GC-rich region | |
| Hagenbüchle et al. | Conservation of the primary structure at the 3′ end of 18S rRNA from eucaryotic cells | |
| Braich et al. | Regiospecific solid-phase synthesis of branched oligonucleotides. Effect of vicinal 2 ‘, 5 ‘-(or 2 ‘, 3 ‘-) and 3 ‘, 5 ‘-phosphodiester linkages on the formation of hairpin DNA | |
| MXPA05001355A (es) | Formas nuevas adicionales de moleculas de arn de interferencia. | |
| Beaudry et al. | An efficient strategy for the synthesis of circular RNA molecules | |
| EP1185546A4 (de) | Hochspezifische primer, expressionsverfahren und "kit" | |
| Gryaznov et al. | RNA mimetics: oligoribonucleotide N3′→ P5′ phosphoramidates | |
| JP2002514080A (ja) | 酵素ｄｎａ分子 | |
| Debreuil et al. | Conformation and structural fluctuations of a 218 nucleotides long rRNA fragment: 4-thiouridine as an intrinsic photolabelling probe | |
| Schmid et al. | The secondary structure of guide RNA molecules from Trypanosoma brucei | |
| Leydier et al. | 4′-thio-RNA: synthesis of mixed base 4′-thiooligoribonucleotides, nuclease resistance, and base pairing properties with complementary single and double strand | |
| Frech et al. | Uridine insertion into preedited mRNA by a mitochondrial extract from Leishmania tarentolae: stereochemical evidence for the enzyme cascade model | |
| EP3040423A3 (de) | Mikro-rna und verwendung davon | |
| US6307041B1 (en) | Circular, hairpin, circular/hairpin, lariat, and hairpin-lariat hammerhead ribozymes | |
| Lampe et al. | Factors influencing the extent and selectivity of alkylation within triplexes by reactive G/A motif oligonucleotides | |
| Sergeyev et al. | Catalytic site-specific cleavage of a DNA-target by an oligonucleotide carrying bleomycin A5 | |
| WO2005010188A3 (en) | Rnas able to modulate chromatin silencing | |
| Milne et al. | Oligoribonucleotide-based gene-specific transcription inhibitors that target the open complex | |
| EP0931090B1 (de) | Verbesserte chimäre oligonukleotidvektoren | |
| Studier et al. | Processing of bacteriophage T7 RNAs by RNase III | |
| Obika et al. | 2′, 4′-BNA bearing unnatural nucleobases: Toward the expansion of the target sequence of double-stranded DNA in triplex formation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |